GH Research (NASDAQ:GHRS) Stock Price Down 4.6% - Should You Sell?

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) fell 4.6% during mid-day trading on Tuesday . The stock traded as low as $12.92 and last traded at $13.07. 65,298 shares traded hands during trading, a decline of 65% from the average session volume of 184,651 shares. The stock had previously closed at $13.70.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GHRS. Guggenheim decreased their price objective on shares of GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Stifel Nicolaus increased their price target on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Royal Bank of Canada began coverage on GH Research in a report on Friday, March 7th. They set an "outperform" rating and a $31.00 price target for the company. Cantor Fitzgerald started coverage on GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price objective for the company. Finally, Wall Street Zen cut GH Research from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

GH Research Price Performance

The business's 50 day simple moving average is $10.51 and its 200-day simple moving average is $10.30. The stock has a market capitalization of $717.47 million, a P/E ratio of -17.46 and a beta of 0.97.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.42. Research analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after purchasing an additional 3,092 shares during the period. AdvisorShares Investments LLC lifted its holdings in GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after acquiring an additional 4,806 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in GH Research in the fourth quarter valued at about $44,000. Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in shares of GH Research in the 1st quarter valued at approximately $142,000. Institutional investors and hedge funds own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).